ABBV stock forecast, quote, news & analysis

Key Takeaways

• AbbVie shares surged approximately 17.6% over the last 30 days, climbing from around $216 to above $254, driven by a transformative acquisition and favorable regulatory developments.
• The $10.9 billion acquisition of Apogee Therapeutics (APGE) on June 22 was the single largest catalyst, reinforcing AbbVie's long-term immunology pipeline well into the 2030s.
• Regulatory wins — including Skyrizi label expansion for pediatric psoriasis and a positive EMA committee recommendation for Rinvoq in alopecia areata and vitiligo — added momentum.
• Multiple Wall Street firms, including Wells Fargo and Cantor Fitzgerald, reiterated positive ratings and raised price targets following the Apogee deal announcement.
• Over the broader quarter, ABBV has gained roughly 22%, recovering from late-April lows near $197 to current levels above $254.

AbbVie (ABBV) Company Overview and Market Position

AbbVie is a global, research-driven biopharmaceutical company headquartered in North Chicago, Illinois. The company develops and commercializes advanced therapies across several key therapeutic areas, including immunology, oncology, neuroscience, and aesthetics through its Allergan Aesthetics portfolio. AbbVie's immunology franchise remains its most significant revenue driver, anchored by blockbuster drugs Skyrizi and Rinvoq, which together generated $6.6 billion in net revenue in the first quarter of 2026 alone. The company successfully navigated the post-Humira era following biosimilar competition and has established itself as a Dividend King with over 54 consecutive years of dividend increases. With a market capitalization exceeding $400 billion, AbbVie is one of the largest pharmaceutical companies in the world and a core holding for many institutional and retail investors seeking exposure to the healthcare sector.

AbbVie (ABBV) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AbbVie shares delivered a pronounced upward move of approximately 17.6%, rising from a closing price of $216.49 on June 18 to $254.49 by July 17. The rally was concentrated in late June, when the stock surged more than 6% in a single session following the Apogee Therapeutics acquisition announcement, and continued grinding higher through mid-July on follow-on regulatory catalysts.

Zooming out to the quarterly view, ABBV has gained roughly 22% over the past three months. The stock bottomed near $197 in late April amid broader market pressure before recovering to the $210–$215 range by late May. The Apogee deal in late June served as the inflection point that propelled shares decisively above the $240 level, and subsequent upward momentum carried the stock above $254. The quarterly trend reflects a clear shift from range-bound trading to a breakout driven by strategic conviction around AbbVie's long-term pipeline durability.

What Drove ABBV Stock Price in the Last 30 Days

The dominant catalyst was AbbVie's announcement on June 22 that it would acquire clinical-stage biotech Apogee Therapeutics (APGE) for $135.11 per share in cash, valuing the deal at approximately $10.9 billion. The acquisition brings Apogee's lead candidate zumilokibart — a Phase III-ready, long-acting anti-IL-13 monoclonal antibody for atopic dermatitis — directly into AbbVie's immunology portfolio. Investors rewarded the deal because it directly addressed one of the market's most persistent concerns: how AbbVie plans to sustain growth once Skyrizi and Rinvoq eventually face patent expirations. The transaction, AbbVie's largest in more than five years, signaled that management is proactively building the next generation of immunology blockbusters.

Beyond the acquisition, AbbVie secured several regulatory wins that amplified positive sentiment. The company received U.S. and European approval to expand Skyrizi's label to include pediatric patients with moderate-to-severe plaque psoriasis, broadening its addressable market. Shortly thereafter, the European Medicines Agency's advisory committee recommended approving Rinvoq for two new autoimmune indications — alopecia areata and vitiligo — further diversifying the drug's revenue base. These developments reinforced the narrative that AbbVie's existing growth drivers still have meaningful runway.

Wall Street analysts responded favorably. Wells Fargo maintained an Overweight rating with a $260 price target, while Cantor Fitzgerald reiterated its Overweight rating, projecting the Apogee deal could add 100–150 basis points to top-line growth during the 2031–2035 period. S&P Global Ratings also upgraded AbbVie's outlook to positive, citing the strong revenue trajectory of Skyrizi and Rinvoq.

What Drove ABBV Stock Performance Over the Last Quarter

AbbVie's quarterly performance reflects a broader recovery and strategic repositioning narrative. The stock started the quarter under pressure, touching lows near $197 in late April as investors weighed macroeconomic uncertainty and the pharmaceutical sector faced a modest rotation out of defensive names. However, strong first-quarter earnings — highlighted by Skyrizi's 29% year-over-year sales growth to $4.5 billion and Rinvoq's 20% increase to $2.1 billion — provided a fundamental floor. Through May, the stock steadily recovered to the $210–$218 range as confidence in the immunology franchise solidified.

The Apogee acquisition then transformed the quarterly story from steady recovery into a growth-repricing event. The deal demonstrated that AbbVie is not simply managing its current portfolio but actively building a pipeline capable of delivering mega-blockbuster revenue in the next decade. Additional pipeline progress — including FDA approval of Decnupaz for a rare blood cancer and continued expansion of the neuroscience franchise led by Vyalev for Parkinson's disease — underscored that AbbVie's growth engines extend beyond immunology alone.

Trending AI Robots

For traders seeking data-driven insights beyond traditional analysis, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of tickers across a broad range of strategies, timeframes, and risk profiles. Only the most relevant and consistently high-performing bots are featured in this section, making it a practical starting point for those interested in algorithmic trading signals. Each bot employs distinct methodologies — from trend following to pattern recognition — and displays transparent performance metrics. Whether you are monitoring pharmaceutical stocks like AbbVie or scanning the broader market, exploring the Trending AI Robots page can help identify actionable trading ideas powered by real-time AI analysis.

ABBV Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, AbbVie's second-quarter 2026 earnings report, scheduled for July 31, will be the most immediate catalyst. Investors will scrutinize Skyrizi and Rinvoq revenue figures, updated full-year guidance, and management's commentary on the Apogee integration timeline. The transaction is expected to close in the third quarter, and any updates on regulatory approval progress will be closely monitored.

Beyond earnings, key factors to watch include Phase III trial initiation for zumilokibart in atopic dermatitis, the European Commission's final decision on Rinvoq's expanded indications, and competitive dynamics with Sanofi (SNY) and Regeneron (REGN), whose blockbuster Dupixent dominates the atopic dermatitis market. Macroeconomic variables — including interest rate policy, healthcare sector regulation, and drug pricing legislation — remain relevant background risks. While the Apogee deal has meaningfully improved AbbVie's long-term growth outlook, the company has signaled the transaction will not become earnings-accretive until 2032, meaning near-term dilution and pipeline execution risk warrant continued attention.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations